Article Text

Download PDFPDF

Eptastigmine led to cognitive, clinical, and functional benefits in Alzheimer's disease

Statistics from

OpenUrlAbstract/FREE Full Text

Question In patients with moderate to moderately severe Alzheimer's disease (AD), how effective and safe is eptastigmine?


Randomised, double blind, placebo controlled trial with 24 weeks of follow up.


36 centres in the US and Europe.


491 patients (mean age 71 y, 63% women) who met the diagnostic criteria for AD established by the NINCDS-ADRDA and described by DSM-IV, and who had a cognitive deficit for ≥6 months, a Mini-Mental State Examination Scale score between 10 and 22, a Global Deterioration Scale rating of 4 or 5, a modified Hachinski ischaemic score <3, and a Hamilton Depression Scale score <18. Exclusion criteria were other neurological or psychiatric disorders; renal, hepatic, or cardiovascular diseases; peptic ulcer; bronchial asthma; neutropenia; deficiencies in thyroxine, vitamin B12, or folate; or treatment with medication known to affect the central nervous system. 86% completed the study.


164 patients were assigned to placebo, 166 to 15 mg 3 times daily of eptastigmine, and 161 to 20 mg 3 times daily of eptastigmine for a period of 24 weeks. Eptastigmine was given using a 4 week stepwise dose escalation starting from 5 …

View Full Text

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.